Overview

Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
To assess the effect of pimavanserin on the activities of daily living in subjects with Parkinson's Disease Psychosis
Phase:
Phase 4
Details
Lead Sponsor:
ACADIA Pharmaceuticals Inc.
Treatments:
Pimavanserin